Literature DB >> 32284322

Novel preoperative predictive score to evaluate lymphovascular space involvement in endometrial cancer: an aid to the sentinel lymph node algorithm.

Vito Andrea Capozzi1, Giulio Sozzi2, Stefano Uccella3, Valentina Ceni4, Alessandra Cianciolo4, Giulia Gambino4, Giulia Armano4, Martina Pugliese4, Giovanni Scambia5, Vito Chiantera6,7, Roberto Berretta4.   

Abstract

INTRODUCTION: Sentinel lymph node (SLN) dissection has been recognized as a valid tool for staging in patients with endometrial cancer. Several factors are predictors of recurrence and survival in endometrial cancer, including positive lymphovascular space invasion. The aim of this study is to formulate a pre-operative score that, in the event of no-SLN identification, may give an estimate of the true probability of lymphovascular space invasion and guide management.
METHODOLOGY: This was a multi-institutional retrospective study conducted from January 2007 to December 2017. We included all patients with any grade endometrial tumor with a complete pathological description of the surgical specimen and with a minimum follow-up of 12 months. All patients underwent a class A hysterectomy according to Querleu and Morrow and bilateral salpingo-oophorectomy. Lymphadenectomy was performed based on patient risk of node metastases. In order to verify the predictive capacity of the parameters associated with lymphovascular space invasion status, grading, abnormal CA125 (>35 units/ml), myometrial invasion, and tumor size, a synthetic score was calculated. The score was introduced in the receiver operating characteristic curve model in which the binary classifier was represented by the lymphovascular space invasion status. The ideal cut-off was calculated with the determination of the Youden index. Sensitivity and negative predictive value of lymphovascular space invasion score was calculated in patients with lymph node metastasis.
RESULTS: Six hundred and fourteen patients were included in the study. The average age and BMI of patients were 64.8 (range 33-88) years and 30.1 (range 17-64) respectively. Of the 284 patients who underwent lymphadenectomy, 231 (81.3%) patients had no lymph node metastases, 33 (11.6%) patients had metastatic pelvic lymph nodes, 12 (4.2%) patients had metastatic aortic lymph nodes, and eight (2.8%) patients had both pelvic and aortic metastatic lymph nodes. Lymphovascular space invasion was associated with deep myometrial infiltration (P<0.001), G3 grading (P<0.001), tumor size ≥25 mm (P=0.012), abnormal CA125 (P<0.001), recurrence (P<0.001), overall survival (P<0.001), and disease-free survival (P<0.01). Of all patients with lymphovascular space invasion, 79% had an lymphovascular space invasion score ≥5. The score ranged from a minimum score of 1 to a maximum of 7. The score shows 78.9% sensitivity (95% CI 0.6971 to 0.8594), 65.3% specificity (95% CI 0.611 to 0.693), 29.4% positive predictive value (95% CI 0.241 to 0.353), and 94.4% negative predictive value (95% CI 0.916 to 0.964).
CONCLUSION: We found that when lymphovascular space invasion score ≤4, there is a very low possibility of finding lymph nodal involvement. The preoperative lymphovascular space invasion score could complement the SLN algorithm to avoid unnecessary lymphadenectomies. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  SLN and lympadenectomy; endometrial neoplasms; lymph nodes; sentinel lymph node; uterine neoplasms

Mesh:

Year:  2020        PMID: 32284322     DOI: 10.1136/ijgc-2019-001016

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Predictive Score of Nodal Involvement in Endometrial Cancer Patients: A Large Multicentre Series.

Authors:  Vito Andrea Capozzi; Giulio Sozzi; Andrea Rosati; Stefano Restaino; Giulia Gambino; Alessandra Cianciolo; Marcello Ceccaroni; Stefano Uccella; Massimo Franchi; Vito Chiantera; Giovanni Scambia; Francesco Fanfani; Roberto Berretta
Journal:  Ann Surg Oncol       Date:  2021-11-26       Impact factor: 5.344

2.  Analysis of Factors Related to Lymph Node Metastasis in Early-Stage Type 1 Endometrial Cancer: Verifying the Clinical Value of Positive Threshold of the Immunohistochemical Parameter Ki67.

Authors:  Peng Jiang; Rui Yuan
Journal:  Cancer Manag Res       Date:  2021-08-10       Impact factor: 3.989

3.  A Lymph Node Count-Based AJCC Staging System Facilitates a More Accurate Prediction of the Prognosis of Patients With Endometrial Cancer.

Authors:  Xinlong Huo; Shufang Wang
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

4.  Can addition of frozen section analysis to preoperative endometrial biopsy and MRI improve identification of high-risk endometrial cancer patients?

Authors:  Go Nakai; Yoshikazu Tanaka; Takashi Yamada; Masahide Ohmichi; Kazuhiro Yamamoto; Keigo Osuga
Journal:  BMC Cancer       Date:  2021-11-04       Impact factor: 4.430

5.  Near-Infrared Imaging With Indocyanine Green for the Treatment of Endometriosis: Results From the Gre-Endo Trial.

Authors:  Luigi Carlo Turco; Giuseppe Vizzielli; Virginia Vargiu; Salvatore Gueli Alletti; Maria De Ninno; Gabriella Ferrandina; Luigi Pedone Anchora; Giovanni Scambia; Francesco Cosentino
Journal:  Front Oncol       Date:  2021-11-15       Impact factor: 6.244

6.  Association of Myometrial Invasion With Lymphovascular Space Invasion, Lymph Node Metastasis, Recurrence, and Overall Survival in Endometrial Cancer: A Meta-Analysis of 79 Studies With 68,870 Patients.

Authors:  Jianzhang Wang; Ping Xu; Xueying Yang; Qin Yu; Xinxin Xu; Gen Zou; Xinmei Zhang
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

Review 7.  Role of uterine manipulator during laparoscopic endometrial cancer treatment.

Authors:  Vito Andrea Capozzi; Andrea Rosati; Stefano Uccella; Gaetano Riemma; Mattia Tarascio; Marco Torella; Pasquale De Franciscis; Nicola Colacurci; Stefano Cianci
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.